BMRN vs. MTD: BioMarin Pharmaceutical vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Profile Item	BMRN	MTD
Name	BioMarin Pharmaceutical Inc.	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	10.85 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	July 26, 1999	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BMRN

MTD

GSPC

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Total Return (1Y)	8.82%	21.58%
Total Return (3Y, Annualized)	-12.54%	19.54%
Total Return (5Y, Annualized)	-7.51%	2.36%

Risk Profile

Drawdown History

BMRN

MTD

GSPC

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Volatility (1Y, Annualized)	35.50%	31.70%
Beta (5Y)	0.24	1.15
Max Drawdown (5Y)	-57.64%	-43.47%
Avg. Volume (3M)	2.28M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

BMRN and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Sharpe Ratio (1Y)	0.13	0.55
Sortino Ratio (1Y)	0.23	0.75

Profitability

ROE (TTM)

Mettler-Toledo (MTD) has no ROE value reported for this period; BioMarin Pharmaceutical (BMRN) reports a negative figure of -0.31%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Max: 109.18%
Q3: 6.23%
BMRN: -0.31%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; BMRN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Mettler-Toledo (MTD) reports 22.25%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
BMRN: -0.52%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Max: 83.12%
BMRN: 26.58%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
ROE (TTM)	-0.31%	--
ROA (TTM)	3.89%	20.09%
Net Margin (TTM)	-0.52%	22.25%
Operating Margin (TTM)	26.58%	28.70%
Gross Margin (TTM)	53.21%	59.16%

Growth

Revenue Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both BioMarin Pharmaceutical (BMRN) at -18.55% and Mettler-Toledo (MTD) at 3.88% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Revenue Growth (YoY)	12.87%	3.98%
Revenue Growth (3Y CAGR)	15.40%	0.90%
EPS Growth (YoY)	-18.55%	3.88%
EPS Growth (3Y CAGR)	33.89%	3.06%

Financial Strength

Current Ratio (MRQ)

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMRN: 2.44
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Max: 1.42
BMRN: 0.67
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Current Ratio (MRQ)	2.44	1.10
Debt / Equity (MRQ)	0.67	26.06
Net Debt / EBITDA	4.04	1.58

Dividends

Dividend Yield (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BMRN: --

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): BMRN does not report P/E ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Mettler-Toledo (MTD) at 8.16 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMRN: 2.97
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioMarin Pharmaceutical (BMRN) at 1.73 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Max: 13.53
Q3: 6.54
Median: 3.25
BMRN: 1.73
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BioMarin Pharmaceutical (BMRN) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioMarin Pharmaceutical (BMRN) and Mettler-Toledo (MTD)
Metric	BMRN	MTD
P/E Ratio (TTM)	--	37.38
P/S Ratio (TTM)	2.97	8.16
P/B Ratio (MRQ)	1.73	442.71
Free Cash Flow Yield (TTM)	-0.15%	1.97%